IDH-mutant glioma

Showing: 1 - 1 of 1 Articles

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma

Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients …